title: Serum agonistic autoantibodies against type-1 angiotensin II receptor titer in patients with epithelial ovarian cancer: a potential role in tumor cell migration and angiogenesis.
abstract: BACKGROUND
  Although agonistic autoantibodies against type-1 angiotensin-II receptor (AT1-AA) are frequently detected in women with preeclampsia, the clinical significance of AT1-AA in association with epithelial ovarian cancer (EOC) has not been identified.
  
  
  METHODS
  In an attempt to clarify this issue, we measured serum AT1-AA titer from EOC patients (n = 89) and healthy normal subjects (n = 55), correlated AT1-AA titer with EOC stage and grade, and demonstrated the effects of purified AT1-AA on migration of ovarian cancer cells and angiogenesis of chick embryo chorioallantoic membrane.
  
  
  RESULTS
  We found that the AT1-AA titer was significantly higher in EOC patients compared with healthy control subjects (1.77 ± 0.28 vs. 0.35 ± 0.05, P < 0.01). The positive rate was averaged by 72.1±2.5% in EOC patients and 15.5 ±1.5% in control (P < 0.01). Increased AT1-AA titer in EOC patients was associated with advanced stages and grades of EOC, and positively correlated with level of vascular endothelial growth factor (r = 0.855, P < 0.01). Furthermore, AT1-AA directly stimulated migration of ovarian cancer cells and enhanced microvascular density of chick embryo chorioallantoic membrane. These AT1-AA-mediated effects were significantly blocked either by an autoantibody-neutralizing peptide or an angiotensin II type I receptor antagonist, losartan.
  
  
  CONCLUSIONS
  Taken together, we found that a higher serum AT1-AA titer may be associated with advanced progression of EOC in patients and play an important role in development of EOC by promoting cancer cell migration and angiogenesis. These findings implicate that AT1-AA might be selected as a detectable biomarker and potential therapeutic target in diagnosis and treatment of EOC patients.
authors.affiliation: Department of Pathophysiology, Capital Medical University, Beijing, P,R, China. liuhr2000@126.com.
authors.forename: Li
authors.initials: L
authors.lastname: Song
authors.forename: Su-Li
authors.initials: SL
authors.lastname: Zhang
authors.forename: Ke-Hua
authors.initials: KH
authors.lastname: Bai
authors.forename: Jie
authors.initials: J
authors.lastname: Yang
authors.forename: Hai-Yan
authors.initials: HY
authors.lastname: Xiong
authors.forename: Xiao
authors.initials: X
authors.lastname: Li
authors.forename: Teng
authors.initials: T
authors.lastname: Liu
authors.forename: Hui-Rong
authors.initials: HR
authors.lastname: Liu
references.citation: J Cell Physiol. 2013 Jan;228(1):142-8
references.pmid: 22566240
references.citation: Obstet Gynecol. 1999 Jan;93(1):21-4
references.pmid: 9916949
references.citation: Clin Cancer Res. 2005 Apr 1;11(7):2686-94
references.pmid: 15814650
references.citation: J Clin Oncol. 2005 Feb 10;23(5):1011-27
references.pmid: 15585754
references.citation: Cancer Res. 2010 Mar 1;70(5):1951-9
references.pmid: 20160026
references.citation: Clin Cancer Res. 2006 Sep 1;12(17):5018-22
references.pmid: 16951216
references.citation: Circulation. 2003 Apr 1;107(12):1632-9
references.pmid: 12668498
references.citation: Am J Cardiol. 2003 Jun 19;91(12A):30H-37H
references.pmid: 12818733
references.citation: Circulation. 2004 Sep 21;110(12):1612-9
references.pmid: 15381659
references.citation: Hypertension. 2009 Oct;54(4):905-9
references.pmid: 19704104
references.citation: Hypertension. 2007 Aug;50(2):269-75
references.pmid: 17576854
references.citation: Am J Physiol. 1993 Feb;264(2 Pt 2):R460-5
references.pmid: 8447504
references.citation: Hypertension. 2013 Feb;61(2):526-33
references.pmid: 23248149
references.citation: J Clin Invest. 2003 Jul;112(1):67-75
references.pmid: 12840060
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1248-59
references.pmid: 11870167
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: J Soc Gynecol Investig. 2003 Feb;10(2):82-93
references.pmid: 12593997
references.citation: Br J Cancer. 2005 Aug 22;93(4):425-34
references.pmid: 16052213
references.citation: Clin Cancer Res. 2001 Apr;7(4):1073-8
references.pmid: 11309359